Location History:
- Philadelphia, PA (US) (2021)
- North Wales, PA (US) (2020 - 2024)
Company Filing History:
3 out of 2,405 
1 out of 64 
1 out of 13 Years Active: 2020-2024
Title: David Ross Kaufman: Innovator in Cancer Treatment
Introduction
David Ross Kaufman is a notable inventor based in North Wales, PA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of combination therapies. With a total of 3 patents, Kaufman has focused on enhancing the efficacy of cancer treatments.
Latest Patents
Kaufman's latest patents include groundbreaking therapies aimed at treating cancer. One of his notable inventions is a combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer. This patent describes combination therapies that utilize an antagonist of the Programmed Death 1 receptor (PD-1) alongside a Toll-like receptor 9 (TLR9) agonist, specifically a CpG-C type oligonucleotide. The aim is to improve treatment outcomes for cancer patients. Another significant patent involves compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist. This invention outlines methods for treating cell proliferation disorders, such as cancer, by administering specific compounds and anti-human PD-1 antibodies to patients in need.
Career Highlights
Throughout his career, Kaufman has worked with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Dynavax Technologies Corporation, where he contributed to the development of innovative cancer therapies. His work has had a lasting impact on the field of oncology.
Collaborations
Kaufman has collaborated with esteemed colleagues, including Robert A. Kastelein and Ying Yu. These partnerships have fostered a collaborative environment that has led to advancements in cancer treatment methodologies.
Conclusion
David Ross Kaufman is a distinguished inventor whose work in cancer treatment has paved the way for innovative therapies. His patents reflect a commitment to improving patient outcomes and advancing medical science. His contributions continue to inspire future research in oncology.